Idiopathic Pulmonary Fibrosis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavo

Idiopathic Pulmonary Fibrosis Pipeline constitutes 80+ key companies continuously working towards developing 100+ Idiopathic Pulmonary Fibrosis treatment therapies, analyzes DelveInsight.

Idiopathic Pulmonary Fibrosis Overview:

Idiopathic pulmonary fibrosis (IPF) is a lung condition characterized by scarring of the lungs with an unknown cause. It typically progresses over time and has a poor long-term outlook. Key symptoms of IPF include increasing shortness of breath and a dry cough. Pulmonary function tests usually show restrictive lung impairment and reduced carbon monoxide diffusing capacity.

Environmental factors such as smoking, chronic aspiration, viral infections, and advancing age are thought to contribute to respiratory epithelial injury, which likely plays a role in the development of IPF. This injury activates fibroblasts and disrupts the repair of the alveolar epithelium. This process leads to excessive matrix buildup in the lung interstitium, causing scarring and destruction of lung structure, ultimately resulting in pulmonary fibrosis. As the lung architecture deteriorates, gas exchange becomes impaired, leading to hypoxic respiratory failure, a key feature of advanced IPF.

The most common initial symptoms of IPF are shortness of breath with exertion and cough, followed by fatigue. Diagnosis is often delayed, with most patients being diagnosed over a year after symptoms begin. Because the symptoms are nonspecific and the cause of the disease is unknown, other conditions must be ruled out before a diagnosis can be made. It's important to ask about exposure to inhaled substances like dust, metals, asbestos, mold, or birds to exclude other types of interstitial lung disease. Diagnosis can often be confirmed without a biopsy if imaging tests, clinical history, and the exclusion of other conditions align. The typical CT scan imaging pattern shows peripheral bilateral fibrosis, particularly at the lung bases. If there is any uncertainty, a lung biopsy can be used to confirm the diagnosis of IPF.

Request for a detailed insights report on Idiopathic Pulmonary Fibrosis pipeline insights @ https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Idiopathic Pulmonary Fibrosis Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Idiopathic Pulmonary Fibrosis Therapeutics Market.

Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report

DelveInsight's Idiopathic Pulmonary Fibrosis pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Idiopathic Pulmonary Fibrosis treatment.
In May 2023, Kinarus Therapeutics announced the signing of a strategic convertible loan agreement for a CHF 1.5 million investment from ChaoDian (Hangzhou) Investment Management Co., Ltd. (CDIM), an investment firm based in Hangzhou, China. This agreement lays the groundwork for discussions regarding the introduction, development, and commercialization of KIN001 for treating idiopathic pulmonary fibrosis (IPF) in China. Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group, facilitated the introduction of CDIM to Kinarus.
In April 2023, AGC Biologics revealed that it had entered into a service agreement with The Jikei University in Japan. Under the agreement, AGC Biologics will undertake a technology transfer and feasibility study for a drug product aimed at treating idiopathic pulmonary fibrosis at its Cell and Gene Excellence center in Milan.
In February 2023, Insilico Medicine announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to INS018_055 for the treatment of idiopathic pulmonary fibrosis (IPF).
Also in February 2023, Arrowhead Pharmaceuticals Inc. reported that it had dosed the first participants in a Phase I/IIa clinical trial of ARO-MMP7, an investigational RNA interference (RNAi) therapeutic designed to reduce matrix metalloproteinase 7 (MMP7) expression as a potential treatment for idiopathic pulmonary fibrosis (IPF).
In February 2023, Daewoong Pharmaceutical, based in South Korea, secured an exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin, a first-in-class PRS inhibitor, for the Greater China region (mainland China, Hong Kong, Taiwan, and Macau). Under the agreement, CS Pharmaceuticals will license Bersiporocin for IPF and potentially other fibrotic conditions, with a total consideration of up to $336 million, including up to $76 million in upfront and development milestone payments and double-digit royalties on net sales.
In January 2023, Insilico Medicine shared positive topline results from the Phase 1 clinical trial of INS018_055, a potential first-in-class drug for idiopathic pulmonary fibrosis (IPF), regarding its safety, tolerability, and pharmacokinetics (PK).
In January 2023, Pliant Therapeutics announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic pulmonary fibrosis (IPF).
Key Idiopathic Pulmonary Fibrosis companies such as FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others are evaluating new drugs for Idiopathic Pulmonary Fibrosis to improve the treatment landscape.
Promising Idiopathic Pulmonary Fibrosis pipeline therapies in various stages of development include Pamrevlumab, Tipelukast, PLN-74809, HZN-825, Brilaroxazine, and others.

Idiopathic Pulmonary Fibrosis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Idiopathic Pulmonary Fibrosis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.

Download our free sample page report on Idiopathic Pulmonary Fibrosis pipeline insights @ https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Idiopathic Pulmonary Fibrosis Emerging Drugs

Pamrevlumab: FibroGen
Tipelukast: MediciNova
PLN-74809: Pliant Therapeutics
HZN-825: Horizon Pharmaceuticals
Brilaroxazine: Reviva Pharmaceuticals

Idiopathic Pulmonary Fibrosis Companies

Over 80 major companies are working on developing therapies for idiopathic pulmonary fibrosis. Among them, FibroGen is one of the companies with drug candidates for idiopathic pulmonary fibrosis in the most advanced stage, Phase III.

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Idiopathic Pulmonary Fibrosis Therapies and Key Companies: Idiopathic Pulmonary Fibrosis Clinical Trials and advancements @ https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment
• Idiopathic Pulmonary Fibrosis Assessment by Product Type
• Idiopathic Pulmonary Fibrosis By Stage
• Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
• Idiopathic Pulmonary Fibrosis Assessment by Molecule Type

Download Idiopathic Pulmonary Fibrosis Sample report to know in detail about the Idiopathic Pulmonary Fibrosis treatment market @ Idiopathic Pulmonary Fibrosis Therapeutic Assessment @ https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Idiopathic Pulmonary Fibrosis Current Treatment Patterns
4. Idiopathic Pulmonary Fibrosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Idiopathic Pulmonary Fibrosis Late-Stage Products (Phase-III)
7. Idiopathic Pulmonary Fibrosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Idiopathic Pulmonary Fibrosis Discontinued Products
13. Idiopathic Pulmonary Fibrosis Product Profiles
14. Idiopathic Pulmonary Fibrosis Key Companies
15. Idiopathic Pulmonary Fibrosis Key Products
16. Dormant and Discontinued Products
17. Idiopathic Pulmonary Fibrosis Unmet Needs
18. Idiopathic Pulmonary Fibrosis Future Perspectives
19. Idiopathic Pulmonary Fibrosis Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Idiopathic Pulmonary Fibrosis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.